Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:1455 (28 June), doi:10.1136/bmj.a464
Andrew Jack
1 Financial Times
| The first 150 words of the full text of this article appear below. |
The government and the drug industry this week reached an outline agreement on a new contract for drug prices in the United Kingdom over the next five years. It is expected that the deal will cut the annual £9bn (
11bn; $18bn) drug bill in the UKs health services by 5% by 2009.
The announcement follows a year of intense and tough negotiations after the Department of Health said it was unilaterally cancelling the current pharmaceutical price regulation scheme (PPRS) halfway through its planned duration (BMJ 2007;335:273 doi: 10.1136/bmj.39300.405822.DB).
The PPRS, which normally runs for five years, allows companies to set drug prices freely but caps their overall profits. The current scheme began in 2005, with a 7% price cut, and was supposed to end in 2010.
Under pressure to cut costs at a time when the growth in the NHS budget is slowing, the government sought a
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?